See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Nintendo
Baseball
Donald Trump
Natural Disasters
Social Media
European Union
Taxes
Trade War
Trade
Golf
Senate
Published • loading... • Updated

[Opinion] TREMFYA receives positive CHMP opinion for treatment of patients with Crohn's

Summary by European Pharmaceutical Manufacturer
Johnson & Johnson has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expanding the Marketing Authorisation for TREMFYA (guselkumab).
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
European Pharmaceutical ManufacturerEuropean Pharmaceutical Manufacturer

TREMFYA receives positive CHMP opinion for treatment of patients with Crohn's

Johnson & Johnson has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expanding the Marketing Authorisation for TREMFYA (guselkumab).

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

European Pharmaceutical Manufacturer broke the news in on Monday, March 31, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Opinion

Opinion

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal